Journal article
Variable CD341 recovery of cryopreserved allogeneic HPC products: Transplant implications during the COVID-19 pandemic
D Purtill, V Antonenas, P Chiappini, D Tong, E O’Flaherty, A Bajel, K Kabani, S Larsen, S Tan, C Hutchins, DJ Curtis, GA Kennedy, AM Watson, LJ Bai, M Greenwood, DJ Gottlieb, N Hamad
Blood Advances | AMER SOC HEMATOLOGY | Published : 2020
Abstract
Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD341 cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD341 cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, whi..
View full abstract